default author photo

Frederik Marmé

Leitung Sektion Translationale Gynäkologische Onkologie Nationales Centrum für 27 Tumorerkrankungen und Universitätsfrauenklinik Heidelberg

Grabengasse 1

Heidelberg, 69117

Germany

SCHOLARLY PAPERS

2

DOWNLOADS

197

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Low Positivity for Hormone Receptors in Early Breast Cancer: Therapy-Response and Prognosis -A Systematic Analysis of a Total of 9027 Patients

Number of pages: 33 Posted: 22 Dec 2019
Free University of Berlin (FUB), German Breast Group (GBG Forschungs GmbH), Ludwig Maximilian University of Munich (LMU), Helios Klinikum Niederberg, Ludwig Maximilian University of Munich (LMU), St. Barbara Klinik, Mittelbaden Hospital, University of Erlangen-Nuremberg-Friedrich Alexander Universität Erlangen Nürnberg, German Breast Group (GBG Forschungs GmbH), Institute of Pathology Düren, Leitung Sektion Translationale Gynäkologische Onkologie Nationales Centrum für 27 Tumorerkrankungen und Universitätsfrauenklinik Heidelberg, Friedrich-Alexander-Universität Erlangen-Nürnberg, Rotkreuzklinikum, Free University of Berlin (FUB), Ulm University, German Breast Group (GBG Forschungs GmbH), Schleswig-Holstein University, Bethanien Hospital, Sana Klinikum Offenbach, Luisenkrankenhaus, Heidelberg University, Free University of Berlin (FUB), Marien Hospital Witten, Technische Universität München (TUM), University of Erlangen-Nuremberg-Friedrich Alexander Universität Erlangen Nürnberg, Technische Universität München (TUM) - Klinikum Rechts der Isar, Free University of Berlin (FUB) and German Breast Group (GBG Forschungs GmbH)
Downloads 121 (592,433)

Abstract:

Loading...

Hormone receptor, neoadjuvant, therapy Response, prognosis, breast cancer, endocrine therapy, triple-negative

2.

Chemotherapy De-Escalation Using an 18F-FDG PET/CT–Based, Pathologic Response–Adapted Strategy in HER2-Positive Early Breast Cancer: The PHERGain Trial

Number of pages: 38 Posted: 02 Dec 2020
Quiron Group - International Breast Cancer Center (IBCC), Université Libre de Bruxelles (ULB) - Institute Jules Bordet, Hospital Universitario Virgen del Rocío - Medical Oncology Department, Institut Català d'Oncologia, Hospital Clínico Universitario de Valencia, Queen Mary University of London - Barts ECMC, Leitung Sektion Translationale Gynäkologische Onkologie Nationales Centrum für 27 Tumorerkrankungen und Universitätsfrauenklinik Heidelberg, Vall d'Hebron University Hospital - Breast Cancer Group, Hospital Universitario A Coruña - UGC Oncología Intercentros, Hospital Universitario Virgen de la Victoria, Universidad de Alcalá, IRYCIS, Hospital Universitari Sant Joan de Reus - Department of Medical Oncology, Hospital Clinic of Barcelona - Department of Medical Oncology, Institut Claudius Regaud - IUCT-Oncopole, CRCT, Inserm, Sorbonne University - Tenon Hospital, Nuclear Medicine and PET Center Department, European Institute of Oncology (IEO) - Division of Medical Senology, Universidade do Porto - Centro Hospitalar, Medica Scientia Innovation Research (MEDSIR), Medica Scientia Innovation Research (MEDSIR), Vall d'Hebron Institute of Oncology, Universidad Catolica - Hospital Arnau de Vilanova and Independent
Downloads 76 (830,555)

Abstract:

Loading...

Trastuzumab; Pertuzumab; De-escalation; Pathologic complete response; FDG-PET/CT; HER2-positive; Early breast cancer